Evotec's Quarter Nears Breakeven, but the Nine-Month Ledger Still Reads Deep Red

Evotec shares drew two different readings of the same tape on Tuesday. One tally had the stock up 4.0%, another 5.0%, both crediting the same pair of drivers: visible progress in the restructuring and a full-year outlook left untouched. What the rally did not come with was a fresh upgrade.

RBC kept Evotec at "Outperform" with a 5-euro price target, and analyst Charles Weston noted that the final quarterly figures matched the preliminary numbers the company had already flagged. The endorsement therefore accompanies the move rather than propelling it — a distinction that matters for anyone treating the session's gain as a new valuation step.

A quarter that moved close to the line

Between July and September 2026, Evotec posted revenue of EUR 164.9 million and an adjusted EBITDA of minus EUR 1.6 million. The loss on that line shrank from minus EUR 15.0 million a year earlier, an 89.1% improvement by the company's own accounting. Sales also came in above the level of the two preceding quarters.

That is a genuine operating step, not window dressing. The caveat is baked into the word "adjusted": the figure is not a net profit, and it argues for better operations rather than a completed turnaround. Nor does one stronger quarter say anything reliable about how evenly the improvement will carry forward.

The cumulative numbers tell the harder story

Over the first nine months of 2026, revenue fell to EUR 465.0 million from EUR 535.1 million in the prior-year period. Adjusted EBITDA for the same stretch came in at minus EUR 44.3 million, compared with minus EUR 16.9 million a year earlier.

Set the two pictures side by side and the tension in the equity story becomes clear. A company can improve in its latest quarter and still finish a longer stretch meaningfully weaker. Investors who fixate on the encouraging quarterly swing underrate the drag; those who look only at the decline miss the progress. Improvement and recovery are not the same thing, and the nine-month ledger is the counterweight to the quarterly headline.

Guidance held, not raised

For the full year, Evotec reiterated a revenue range of EUR 570 million to EUR 610 million and an adjusted EBITDA outlook of minus EUR 105 million to minus EUR 70 million. A confirmed forecast offers orientation, but it is neither an increase nor a promise that the recent quarterly momentum persists. The expected annual loss on that measure remains part of the picture.

The medium-term ambitions have been adjusted rather than abandoned. Evotec is targeting revenue of around EUR 1 billion by 2030, with an adjusted EBITDA margin of 20% of sales by the end of 2028 and above 20% by the end of 2030. Reaching profitability is only half of that equation; the timeline to the intended earning power is the other half, and it still demands patience.

What would settle the argument

The market's positive reception is understandable given measurable operating improvement and a reaffirmed framework. The more persuasive case for a recovery, though, rests on repetition — the approach toward breakeven on adjusted EBITDA needs to recur before it can anchor a re-rating. Until then, the quarter earns recognition while the long-range targets carry a burden of proof.